What is an SEC 13F filing?

SEC 13F is a quarterly report filed with the U.S. Securities and Exchange Commission by institutional investment managers with over $100 million in assets. It must be filed within 45 days after each quarter ends. FolioObs analyzes these filings to track portfolio changes of legendary Wall Street investors.

How can I track Cathie Wood's ARK daily trades?

ARK Invest publicly discloses its daily trades. FolioObs updates this data daily so you can see Cathie Wood's buys and sells in real-time on the dashboard.

Which investors does FolioObs track?

FolioObs tracks 50 legendary investors — known as the FolioObs 50 — including Warren Buffett (Berkshire Hathaway), Cathie Wood (ARK Invest), Ken Griffin (Citadel), Carl Icahn, Paul Singer (Elliott), Masayoshi Son (SoftBank Group), Ray Dalio (Bridgewater), Terry Smith (Fundsmith), Joel Greenblatt (Gotham), Ron Baron (Baron Capital), and Korea's National Pension Service (NPS).

How often is the portfolio data updated?

SEC 13F data is updated quarterly. Cathie Wood's ARK daily trades are updated every trading day after market close. Stock prices are reflected in real-time with a 15-minute delay.

Is FolioObs free to use?

Yes, FolioObs is completely free. It provides quarterly SEC 13F portfolio tracking for 50 legendary investors, Cathie Wood's daily ARK trades, insider and congressional trade data, AI-powered insights, a stock screener, and investor comparison tools in both Korean and English at no cost.

CHAMPIONS ONCOLOGY INC earnings calls

CSBR · every analyst question and management's answer

Sep 10, 2026 earnings call — Revenue, margin improvement and data growth

Revenue was $15.2 million and adjusted EBITDA was approximately $700,000 in Q1.

Revenue $0.0B (est $0.0B) · EPS $0.05 (est $-0.01)

Key quotes

"Revenue was $15.2 million, compared to $14 million in the first quarter of fiscal '26. Gross margin was 50%, up from 43% in Q1 fiscal '26. Adjusted EBITDA was approximately $700,000 and on a GAAP basis, we reported a net loss of $0.4 million."
— Robert Brainin (CEO) · Financial performance

"Deeply characterized clinically annotated, patient-derived data is scarce, and we have it."
— Robert Brainin (CEO) · Data business growth

"The external conversations continue with both venture groups and potential pharmaceutical partners and the data we're generating continues to strengthen the case."
— Robert Brainin (CEO) · Corellia progress

AI-generated notes on the earnings call transcript. Quotes are taken from the transcript. This is not a FolioObs investment view.

CHAMPIONS ONCOLOGY INC (CSBR) · Earnings calendar